Sartorius Stedim Biotech SA DIM

Stock XPAR Rating as of Sep 30, 2026

€206.20 −6.60 (3.10%)

As of Oct 1, 2026, 3:35:26 PM Delayed Price Closed

Company Report

Sartorius Stedim Biotech: A Pureplay Bet on Biopharma Recovery

Max Jousma Sep 1, 2026

Sartorius Stedim Biotech, a subsidiary of Sartorius AG, is a leading provider of bioprocessing equipment and consumables. It offers a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions and focus as a pure-play biopharmaceutical equipment supplier distinguish SSB from more-diversified competitors. The company reinforces its competitive edge by leading the market in bioreactors, a core component of the biomanufacturing process.

Read Analysis

Price vs Fair Value

View History

DIM is trading at a LOCK|!@V#Lt premium.

Price

€212.80

Sep 30, 2026

Fair Value

<b!

May 7, 2025

Uncertainty

LOCK|p&

1-Star Price: LOCK|n.x%
5-Star Price: LOCK|$.>@
Economic Moat: LOCK|PB
Capital Allocation: LOCK|C^p#N<B

Bulls Say, Bears Say

Bulls

SSB's CGT product portfolio allows the company to capitalize on long-term growth, should these therapies achieve widespread adoption.

Bears

The high growth in the biopharma market increases the risk of greater competition from better-capitalized peers that have a broader product offering.

Trading Information

Previous Close Price: €212.80
Day Range: €205.60–213.40
52-Week Range: €150.00–223.00
Bid/Ask: €205.40 / €212.40
Shares Outstanding: 97.29M
Market Cap: €20.06B
Volume/Avg: 89,732 / 87,298

Key Statistics

Price/Earnings (Normalized): 53.29
Price/Sales: 6.88
Dividend Yield (Trailing): 0.32%
Dividend Yield (Forward): 0.32%
Dividend Payment Schedule: Apr
Total Yield: 0.32%

Company Profile

Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.

Sector: Healthcare
Industry: Medical Instruments & Supplies
Stock Style Box: Mid Core
Total Number of Employees: 10,477
Website: https://www.sartorius.com

Competitors

Valuation

Metric	DIM	MRK	A
Price/Earnings (Normalized)	53.29	17.12	27.50
Price/Book Value	4.89	1.99	6.38
Price/Sales	6.88	2.84	6.41
Price/Cash Flow	34.02	13.19	24.91

Price/Earnings

DIM

MRK

Financial Strength

Metric	DIM	MRK	A
Quick Ratio	0.48	0.99	1.41
Current Ratio	1.16	1.69	2.05
Interest Coverage	4.24	7.22	16.08

Quick Ratio

DIM

MRK

Profitability

Metric	DIM	MRK	A
Return on Assets (Normalized)	5.40%	4.75%	13.27%
Return on Equity (Normalized)	10.62%	8.32%	24.92%
Return on Invested Capital (Normalized)	7.74%	6.65%	16.95%

Return on Assets

DIM

MRK

Medical Instruments & Supplies Industry Comparables

Screen With Investor

Name	Capital Allocation	Economic Moat	Market Cap
Intuitive Surgical Inc ISRG	LOCK\|Sq#%Q!Lv	LOCK\|x^	$142B
Becton Dickinson & Co BDX	LOCK\|@Fs	LOCK\|#$?w	$49B
ResMed Inc RMD	LOCK\|#tfLnx$!	LOCK\|wLg@	$32B
Medline Inc Ordinary Shares - Class A MDLN	LOCK\|^@#?dL	LOCK\|F$FQ>	$31B
Alcon Inc ALC	LOCK\|gJrHn#	LOCK\|!$PN	$31B
West Pharmaceutical Services Inc WST	LOCK\|HTWN^wM	LOCK\|??>	$26B
Solventum Corp SOLV	LOCK\|rrd@@?	LOCK\|yd	$15B
Baxter International Inc BAX	LOCK\|#f	LOCK\|w!!&	$12B
The Cooper Companies Inc COO	LOCK\|j%?HBw	LOCK\|CF&%#	$11B
Align Technology Inc ALGN	LOCK\|Qz?PRZD	LOCK\|K>C@	$10B